Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B

Chinese Medical Journal

Volumn 125, Issue 18, 2012, Pages 3273-3278

  Liu, Ning ^a   Zhao, Li jun ^a   Li, Xiao ping ^a   Wang, Jian liu ^a   Chai, Guo lin ^b   Wei, Li hui ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Apoptosis; DNA methyl transferase; DNA methyltransferase 3B; Histone deacetylase inhibitors; Human cervical cancer; Trichostatin A

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; CRYSTAL VIOLET; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FLUORESCEIN ISOTHIOCYANATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

APOPTOSIS; CELL LINE; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; UTERINE CERVICAL NEOPLASMS;

EID: 84866636136     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.18.014     Document Type: Article

References (17)

1. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001; 58: 728-736.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 2002; 3: 415-428.
3. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002; 9: 322-332.
4. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biol 2009; 107: 600-608.
5. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150-157.
6. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Advances In Cancer Res 2004; 91: 137-168.
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
8. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001; 48 Suppl 1: S17-S19.
9. Warrell RJ, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-1625.
10. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7.
11. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 1998; 95: 10860-10865.
12. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19: 5712-5719.
13. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, et al. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 2008; 3: e2445.
14. Xiong Y, Dowdy SC, Podratz KC, Jin F, Attewell JR, Eberhardt NL, et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 2005; 65: 2684-2689.
15. Arzenani MK, Zade AE, Ming Y, Vijverberg SJ, Zhang Z, Khan Z, et al. Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics. Mol Cell Biol 2011; 31: 4119-4128.
16. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res 2011; 31: 2723-2732.
17. Kuck D, Caulfield T, Lyko F, Medina-Franco JL. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 2010; 9: 3015-3023.